22(S)-hydroxy Cholesterol is a synthetic oxysterol and a modulator of the liver X receptor (LXR). [1] t prevents monocyte chemoattractant protein 1 (MCP-1) expression induced by the LXR agonist GW 3965 in primary hepatocytes and downregulates mRNA expression of the LXR target genes CD36, ACSL1, and SCD-1 in human myotubes. It decreases triacylglycerol and diacylglycerol synthesis from labeled palmitate and acetate, respectively, in human myoblasts by 50% when used at a concentration of 10 uM. 22(S)-hydroxy Cholesterol also reduces fatty acid synthase (FAS) reporter activity through an LXR response element in the promoter region in COS-1 cells transfected with RXRα and LXRα and decreases the expression of MCP-1 and CCR2 in a mouse model of chronic ethanol consumption.[1] [2] Dietary supplementation of 22(S)-hydroxy cholesterol (30 mg/kg per day) leads to less body weight gain and lower liver triacylglycerol levels in rats when fed either a regular chow or high-fat diet as well as preven

TB5 是一种选择性可逆 hMAO-B 有效抑制剂，Ki=0.11±0.01 μM。

PKR activator 4 (example 7A) 是一种高效的丙酮酸激酶 R (pyruvate kinase R (PKR)) 激活剂，展现出研究血液疾病的潜力。

Ac-SVVVRT-NH2 是一种调节PGC-1α启动子（human, 114%）活性的PGC-1α调节剂。该化合物能够在人皮下脂肪细胞中提高PGC-1α的mRNA水平（125%）和促进胞内脂质累积（128%）。因此，Ac-SVVVRT-NH2 对于研究PGC-1α调控的疾病具有潜在应用价值。

MK-0952 is a selective PDE4 inhibitor used to treat long-term memory loss and mild cognitive impairment. It is an intrinsically potent inhibitor and has shown limited whole blood activity.

L791943 is a selective, potent) inhibitor of Phosphodiesterase-4 (PDE4,IC50 of 4.2 nM).